Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Steven A. Nichtberger
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 156
- Beta
- 3.26
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -0.50
Financials
Net Income
$-51.02MEBITDA
$-49.42MFree Cash Flow
$-41.51MEPS (diluted)
$-0.34Shares Outstanding (diluted)
151.16M+6288.9%Operating Expenses
$52.02MCash & Debt
$225.10MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-167.86M | $-1.64 |
| 2024 | $0.00 | $-115.86M | $-2.34 |
| 2023 | $0.00 | $-67.67M | $-1.65 |
| 2022 | $0.00 | $-52.98M | $-1.81 |
| 2021 | $0.00 | $-46.29M | $-1.80 |
| 2020 | $0.00 | $-33.34M | $-1.44 |
| 2019 | $0.00 | $-16.94M | $-4.07 |
| 2018 | $0.00 | $-12.20M | $-0.84 |
| 2017 | $0.00 | $-250.0K | $-0.01 |
Valuation
CABAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
93+16.67%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·1d ago·Neutral
Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concerns Cabaletta Bio is rated Buy, trading 40% below its $2.41 pipeline value despite a single-asset risk profile. CABA's lead CAR T asset, rese-cel, targets severe autoimmune diseases with pivotal Phase 1/2 data expected mid-2027 and BLA submission planned for late 2027. A recent 10-year manufacturing deal with Cellares lowers future COGS, supporting margin expansion if rese-cel is approved.
View source ↗ - Newsseekingalpha.com·29d ago·Positive
Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·62d ago·Negative
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel
View source ↗
Earnings
Mon, Nov 9(in 4 weeks)
Consensus estimate $-0.33 per share
Typical surprise +4.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.34 vs $-0.37beat
- Thu, May 14$-0.39 vs $-0.41beat
- Mon, Mar 23$-0.40 vs $-0.45beat
- Mon, Nov 10$-0.44 vs $-0.49beat
- Thu, Aug 7$-0.73 vs $-0.71miss
- Thu, May 15$-0.71 vs $-0.67miss
Estimates and results for CABA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CABA officers and directors.
- Bought
- $296k
- Sold
- —
8 trades
0 trades
- Chang David J.bought
- Binder Gwendolynbought
- Tomasello Shawnbought
- Gavel Stevebought
- Bollard Catherinebought
- Nichtberger Stevenbought
- Simon Markbought
- Gerard Michaelbought
92 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CABA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.